Article Sidebar
Views PDF: 310
CONSTRUCT THE MODEL OF COST – EFFECTIVENESS ANALYSIS OF ISAVUCONAZOLE IN INVASIVE ASPERGILLOSIS TREATMENT IN VIETNAM
Main Article Content
Abstract
Invasive Aspergillosis (IA) is a severe form of Aspergillus fungal infection, which common in immunocompromised patients. Isavuconazole (ISA) has been shown to replace other therapies in the treatment of IA with superior clinical efficacy demonstrated in clinical trials. With the modeling method combined with document review and consultation with clinical experts, the CEA model in the treatment of IA in Vietnam has been built using Microsoft Excel software with the following configuration: the model structure includes 2 treatment options with input parameters (probability, cost, effectiveness) from which to estimate output parameters (increase cost-effectiveness ratio and probabilistic sensitivity of model). The model allows to conduct CEA of the 2 regimens and can draw conclusions about the economic efficiency of the optimal effective therapy with minimal cost in the treatment of IA.
Article Details
Keywords
Cost-effectiveness analysis, isavuconazole, Invasive Aspergillosis, model
References
2. Floros L. et al. (2019), "Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden", BMC Infectious Dieases. 19 (134), pp. 1-11.
3. Floros L. et al. (2020), "The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom", Journal of Medical Economics. 23, pp. 86-97.
4. Harrington R. et al. (2016), "Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis", Adv Ther. 34, pp. 207-220.
5. Schmiedel Y. et al. (2016), "Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia", Swiss Medical Weekly, pp. 1-12.